Issue link:

Contents of this Issue


Page 1 of 26

Advantages of Our Biomanufacturing Approach • Seamless transition from clinical to commercial scale • Eliminates risk to process and product as you scale • More exible and ecient process validation • Utilizes benets of disposable technologies Expanding to 270,000 L across 4 countries by 2022 Leading the Industry in Scale-Out Biomanufacturing The world's leading global single-source platform from concept to commercialization

Articles in this issue

Archives of this issue

view archives of BioPharm - BioPharm0619-SingleUseSystems